Skip to search formSkip to main contentSkip to account menu

CI 966

Known as: CI-966 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
GRID-independent molecular descriptor analysis and molecular docking studies to mimic the binding hypothesis of γ-aminobutyric acid transporter 1 (GAT1) inhibitors
Background The γ-aminobutyric acid (GABA) transporter GAT1 is involved in GABA transport across the biological membrane in and… 
2001
2001
Synthesis of novel gamma-aminobutyric acid (GABA) uptake inhibitors. 5.(1) Preparation and structure-activity studies of tricyclic analogues of known GABA uptake inhibitors.
On the basis of the SAR of a series of known gamma-aminobutyric acid (GABA) uptake inhibitors, including 4 (SKF 89976), new… 
1994
1994
Discriminative stimulus effects of presynaptic GABA agonists in pentobarbital-trained rats
1993
1993
Pharmacokinetics, Mass Balance, and Induction Potential of a Novel GABA Uptake Inhibitor, CI-966 HC1, in Laboratory Animals
CI-966 exhibits anticonvulsant properties in various animal models. The drug acts by inhibiting synaptic uptake of γ-aminobutyric… 
1990
1990
Systemic CI-966, a new gamma-aminobutyric acid uptake blocker, enhances gamma-aminobutyric acid action in CA1 pyramidal layer in situ.
A new potent, blood-brain barrier permeable gamma-aminobutyric acid (GABA) uptake blocker, 1-[2-[bis[4-(trifluoromethyl)-phenyl… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)